Edvard Zhavrid

1.4k total citations
35 papers, 640 citations indexed

About

Edvard Zhavrid is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Biomedical Engineering. According to data from OpenAlex, Edvard Zhavrid has authored 35 papers receiving a total of 640 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 11 papers in Biomedical Engineering. Recurrent topics in Edvard Zhavrid's work include Photodynamic Therapy Research Studies (11 papers), Nanoplatforms for cancer theranostics (8 papers) and Biosimilars and Bioanalytical Methods (7 papers). Edvard Zhavrid is often cited by papers focused on Photodynamic Therapy Research Studies (11 papers), Nanoplatforms for cancer theranostics (8 papers) and Biosimilars and Bioanalytical Methods (7 papers). Edvard Zhavrid collaborates with scholars based in Belarus, United States and Poland. Edvard Zhavrid's co-authors include Genady Kostenich, Sergey Sheleg, Sang Joon Lee, Sungyoung Lee, Alexey Manikhas, Vladimir Moiseyenko, Justin Stebbing, Joanna Pikiel, Alexandru Eniu and Andriy Rusyn and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Edvard Zhavrid

33 papers receiving 622 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Edvard Zhavrid Belarus 13 250 222 216 182 133 35 640
Zengfu Zhang China 10 159 0.6× 251 1.1× 108 0.5× 129 0.7× 101 0.8× 22 675
Mary‐Keara Boss United States 11 205 0.8× 161 0.7× 126 0.6× 66 0.4× 98 0.7× 41 616
Omoruyi Credit Irabor United States 5 264 1.1× 578 2.6× 212 1.0× 345 1.9× 161 1.2× 9 961
Awalpreet S. Chadha United States 11 254 1.0× 352 1.6× 173 0.8× 37 0.2× 106 0.8× 19 732
Morten Persson Denmark 17 210 0.8× 352 1.6× 157 0.7× 56 0.3× 305 2.3× 25 876
George A. Luiken United States 16 239 1.0× 202 0.9× 515 2.4× 57 0.3× 80 0.6× 24 858
Songbing Qin China 14 206 0.8× 440 2.0× 127 0.6× 239 1.3× 164 1.2× 54 789
Colby S. Shemesh United States 15 145 0.6× 373 1.7× 174 0.8× 268 1.5× 72 0.5× 33 899
Bin Ji China 16 307 1.2× 173 0.8× 395 1.8× 80 0.4× 170 1.3× 60 1.0k
Andrew Macann New Zealand 11 207 0.8× 281 1.3× 209 1.0× 64 0.4× 49 0.4× 24 936

Countries citing papers authored by Edvard Zhavrid

Since Specialization
Citations

This map shows the geographic impact of Edvard Zhavrid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edvard Zhavrid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edvard Zhavrid more than expected).

Fields of papers citing papers by Edvard Zhavrid

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edvard Zhavrid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edvard Zhavrid. The network helps show where Edvard Zhavrid may publish in the future.

Co-authorship network of co-authors of Edvard Zhavrid

This figure shows the co-authorship network connecting the top 25 collaborators of Edvard Zhavrid. A scholar is included among the top collaborators of Edvard Zhavrid based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edvard Zhavrid. Edvard Zhavrid is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Buske, Christian, Wojciech Jurczak, Juan‐Manuel Sancho, et al.. (2021). Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study. Blood Advances. 5(17). 3354–3361. 6 indexed citations
2.
Stebbing, Justin, Alexey Manikhas, Vladimir Moiseyenko, et al.. (2021). Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial. Breast Cancer Research and Treatment. 188(3). 631–640. 15 indexed citations
3.
4.
Esteva, Francisco J., Alexey Manikhas, Vladimir Moiseyenko, et al.. (2019). Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial. Cancer Chemotherapy and Pharmacology. 84(4). 839–847. 25 indexed citations
5.
Ilson, David H., Josep Tabernero, Aliaksandr Prokharau, et al.. (2019). Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy. JAMA Oncology. 6(1). e193531–e193531. 17 indexed citations
6.
7.
Stebbing, Justin, Alexey Manikhas, Vladimir Moiseyenko, et al.. (2017). CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. The Lancet Oncology. 18(7). 917–928. 94 indexed citations
8.
9.
Esteva, Francisco J., Alexey Manikhas, Vladimir Moiseyenko, et al.. (2017). Double-blind, randomized phase III study to compare the efficacy and safety of trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC). Annals of Oncology. 28. v44–v45. 5 indexed citations
10.
Coiffier, Bertrand, Juan‐Manuel Sancho, Wojciech Jurczak, et al.. (2016). Pharmacokinetic and Safety of CT-P10, a Biosimilar Candidate to the Rituximab Reference Product, in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma (AFL). Blood. 128(22). 1807–1807. 12 indexed citations
11.
12.
Zhavrid, Edvard, et al.. (2005). Whole body hyperthermia in adjuvant therapy of children with renal cell carcinoma. Pediatric Blood & Cancer. 44(7). 679–681. 12 indexed citations
13.
Sheleg, Sergey, et al.. (2004). Photodynamic therapy with chlorin e6 for skin metastases of melanoma. Photodermatology Photoimmunology & Photomedicine. 20(1). 21–26. 98 indexed citations
14.
Sheleg, Sergey, et al.. (2002). Local Chemotherapy with Cisplatin-depot for Glioblastoma Multiforme. Journal of Neuro-Oncology. 60(1). 53–59. 87 indexed citations
15.
Джагаров, Б. М., et al.. (2001). Two‐Color Laser Photodynamic Therapy of Tumors. Journal of Applied Spectroscopy. 68(2). 201–204. 3 indexed citations
16.
Самцов, М. П., et al.. (2001). Fluorescence of the Polymethine Dye Tiks and Diagnostics af Cancer. Journal of Applied Spectroscopy. 68(3). 468–472. 8 indexed citations
17.
Osinsky, Sergej, et al.. (1998). Modifying effect of organocobalt complexes on the tumour response to anticancer treatments.. PubMed. 17(5A). 3457–62. 7 indexed citations
18.
Kostenich, Genady, et al.. (1994). Experimental grounds for using chlorin ρ6 in the photodynamic therapy of malignant tumors. Journal of Photochemistry and Photobiology B Biology. 22(3). 211–217. 88 indexed citations
19.
Kostenich, Genady, et al.. (1993). Sensitivity of different rat tumour strains to photodynamic treatment with chlorin e6. Journal of Photochemistry and Photobiology B Biology. 17(2). 187–194. 9 indexed citations
20.
Kostenich, Genady, et al.. (1991). Photodynamic therapy with chlorin e6. A morphologic study of tumor damage efficiency in experiment. Journal of Photochemistry and Photobiology B Biology. 11(3-4). 307–318. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zengfu Zhang Breakdown of academic impact, for papers by Mary‐Keara Boss Breakdown of academic impact, for papers by Omoruyi Credit Irabor Breakdown of academic impact, for papers by Awalpreet S. Chadha Breakdown of academic impact, for papers by Morten Persson Breakdown of academic impact, for papers by George A. Luiken Breakdown of academic impact, for papers by Songbing Qin Breakdown of academic impact, for papers by Colby S. Shemesh Breakdown of academic impact, for papers by Bin Ji Breakdown of academic impact, for papers by Andrew Macann
Rankless by CCL
2026